compound glp-1 fda says that the shortage is over Compounded Semaglutide & Tirzepatide 2025:

SURPASS-1 shows that tirzepatide alone, at all doses, was superior to placebo and revealed a dose-dependent reduction of HbA1c by up to 2.07% (p 10% weight loss can be disease modifying and may even lead to disease remission [38]

At 48 hours, more patients improved in shock in group 1 (87%vs.63.6% p=0.3), with a reduced incidence of early deaths at day 14 (22.6% 48.5% p =0.03)

Incretin hormones, such as GLP-1 and glucose-dependent insulinotropic polypeptide (GIP), are involved in several functions such as regulating glucose levels, delaying gastric emptying, and reducing food intake [16, 17]

[DOI] [PMC free article] [PubMed] [Google Scholar] 190.Yu L., Quinn M.T., Cross A.R., Dinauer M.C

GLP1 receptor agonists for the treatment of obesity: Role as a promising approach

What are the applications of Glucagon-like peptide-1 (GLP-1) agonists